Indietro

Organon & Co

Ticker: OGN ISIN: US68622V1061
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Mid-cap Dividend payer
Capitalizzazione
3,84 Mld $
P/E
2,95
Forward P/E
5,03
Profit margin
20,30%
Revenue growth QoQ
4,10%
Div. yield
7,51%
Beta
0,80
13,75 $ 0,00%
Prezzo al 2026-08-25 · NYSE

Performance per periodo

Rendimenti cumulativi
1 Month +1,70%
6 Months +83,63%
1 Year +52,83%
5 Years -13,33% p.a.-51,07%
Since inception -12,03% p.a.-49,18%
Rendimenti per anno
YTD +92,81%
2025 -50,71%
2024 +9,92%
2023 -45,12%
2022 -4,86%

Key stats

Market cap
3,84 Mld
P/E
2,95
Dividend yield
7,51%
Beta
0,80
52-week range
12.85 - 22.70
50-day MA
15,84
200-day MA
18,94
Section 1

Business overview

Company profile data from fundamentals.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 0,00%
ROA 7,91%
Profit margin 20,30%
Operating margin 24,65%
Revenue/share TTM 24,98
Revenue TTM 6,41 Mld
EBITDA 1,76 Mld
Gross profit TTM 3,89 Mld
Beta 0,80

Valuation

Trailing P/E 2,95
Forward P/E 5,03
P/B 7,79
P/S 0,60
EV/EBITDA 7,59
EV/Revenue 1,85
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 4,14
Quarterly earnings growth 5,08%
Revenue TTM 6,41 Mld
Reported quarters 18
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 7,51%
Forward annual div. yield 7,51%
Dividend per share 1,1200
Payout ratio 27,38%
Ex-dividend date 2024-11-12
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 29,29 $
Analyst rating 3.3333

Ownership & short interest

Shares outstanding 257,54 Mln
Shares float 256,70 Mln
Institutional ownership 81,64%
Insider ownership 17,70%
Short ratio 5,42
Short % of float 7,91%

Details

Instrument metadata and source update timestamps.

Symbol OGN
Name Organon & Co
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US68622V1061
Country USA
Code + exchange OGN.NYSE
Last price date 2024-12-31
Fundamentals updated 2025-01-01

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.